Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines

This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine. This technology is available for licensing for commercial development as well for further development under a research collaboration.IC: NIAIDNIH Ref. No.: E-195-2014/0Advantages: -broad/universal protection against influenza virusesdoes not require reformulating vaccine each year as done with currently available vaccines on the marketcan potentially provide protection against novel influenza viruses that may arise in future, including potentially pandemic influenza virusesApplications: VaccinesProvider Technology ID: 3081Updated On: Nov 17, 2016Date Published: Friday, November 4, 2016Provider Classifications: Publications: Patent Application: PCT/US2015/02984362/014,821Patent Authority: PCTUSLicensing Contacts: Lead Inventor: Inventor IC: NIAIDInventor Lab URL: http://irp.nih.gov/pi/jeffery-taubenbergerLPM FIrs...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research